Proton pump inhibitors and clopidogrel: Is it a significant drug interaction?

Expert Opinion on Drug Safety

Volumn 9, Issue 4, 2010, Pages 593-602

  Oyetayo, Ola O ^a   Talbert, Robert L ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

acute coronary syndromes; atherosclerosis; clopidogrel; drug interaction; dual antiplatelet therapy; P2Y12 inhibitors; PPIs

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DEXLANSOPRAZOLE; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; GASTROINTESTINAL AGENT; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; REVIEW; THROMBOCYTE AGGREGATION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTE; TREATMENT OUTCOME;

BLOOD PLATELETS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL AGENTS; GASTROINTESTINAL HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TICLOPIDINE; TREATMENT OUTCOME;

EID: 77953790583     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740331003645609     Document Type: Review

References (39)

1. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-Elevation myocardial infarction. Circulation 2008;117:296-329
2. Fraker TD Jr, Fihn SD, Writing on behalf of the 2002 Chronic Stable Angina Writing Committee, et al. 2007 Chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina. Circulation 2007;116:2762-2772
3. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the management of patients with unstable angina/Non-ST-Elevation myocardial infarction. J Am Coll Cardiol 2007;50:e1-157
4. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-1339
5. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
6. Bhatt DL, Keith AAF, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-1717
7. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-2494
8. Patrono C, Baigent C, Hirsh J, et al. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines. 8th edition. Chest 2008;133:199S-233 (Pubitemid 351894914)
9. Bhatt DL, Scheiman J; Writing Committee Members, et al. ACCF/ACG/AHA 2008 Expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents. Circulation 2008;118:1894-1909
10. Juurlink DN, Gomes T, Dennis TK, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-718
11. Ho PM, Thomas MM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-944
12. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735-741
13. Angiolillo DJ, Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am Heart J 2008;156:10S-5S
14. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:66.e9-16
15. Li X, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821-827
16. Gilard M, Arnaud B, Gal GL, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. JTH 2006;4:2508-2509
17. Gilard M, Arnaud B, Jean-Christophe Cornily, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-260
18. Bonello L, Paganelli F, Arpin-bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. JTH 2007;5:1630-1636
19. Siller-Matula J, Alexander OS, Irene ML, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148.e1-5
20. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. JTH 2009;101:714-719
21. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008;52:1038-a-1039
22. Aubert RE, Epstein RS, Teagarden JR, et al. Abstract 3998: proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel Medco outcomes study. Circulation 2008;118:S-815
23. Lau WC, Gurbel PA. The drug-drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:699-700
24. Stanek EJ, Aubert RE, Flockhart DA, et al. A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the clopidogrel Medco outcomes study. SCAI Scientific sessions; 2009
25. Dunn SP, Macaulay TE, Brennan DM, et al. Abstract 3999: baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 2008;118:S815-a
26. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375
27. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989-997
28. Bhatt DL, Cryer B, Contant CF, et al. COGENT: a prospective, randomized, placebo-controlled trial of omeprazole in patients receiving aspirin and clopidogrel. Transcatheter Cardiovascular Therapeutics 2009 Available from: http://assets.cardiosource. com/Bhatt-COGENT.ppt [Last accessed 29 September 2009]
29. Wood S. COGENT-1 trial scrapped, sponsor declares bankruptcy. Theheart org 2009. Available from: www.theheart.org/article/936651.do. [Last accessed 9 October 2009]
30. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-362
31. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613
32. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
33. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037
34. Bhindi R, Ormerod O, Newton J, et al. Interaction between statins and clopidogrel: is there anything clinically relevant? QJM 2008;101:915-925
35. Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). Information for healthcare professionals: Food and Drug Administration, 2009. Available from: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/DrugSafetyInformationforHeathcare Professionals/ucm190787. htm. [Last accessed 17 January 2010]
36. Clopidogrel. Prescribing information. Bristol-Myers Squibb/Sanofi Pharmaceuticals partnership. Bridgewater; 2009
37. Chan FKL, Chung SCS, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-973
38. Taha AS, McCloskey C, Prasad R, et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009;374:119-125
39. Prasugrel. FDA Cardiovascular and Renal Drugs Advisory Committee briefing Document, 2009. Available from: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenal DrugsAdvisoryCommittee/UCM181185. pdf [Last accessed 9 October 2009]